The association between metabolic syndrome and advanced prostate cancer in Chinese patients receiving radical prostatectomy

• Main Authors: Gui-Ming Zhang, Yao Zhu, Da-Hai Dong, Cheng-Tao Han, Cheng-Yuan Gu, Wei-Jie Gu, Xiao-Jian Qin, Li-Jiang Sun, Ding-Wei Ye
• Format: Article
• Language: English
• Published: Wolters Kluwer Medknow Publications 2015-01-01
• Series: Asian Journal of Andrology
• Subjects: Gleason score; metabolic syndrome; pathology; prostate cancer
• Online Access: http://www.ajandrology.com/article.asp?issn=1008-682X;year=2015;volume=17;issue=5;spage=839;epage=844;aulast=Zhang
• ISSN: 1008-682X; 1745-7262

The global incidence of metabolic syndrome (MetS) is dramatically increasing. Considerable interest has been devoted to the relationship between MetS and prostate cancer (PCa) risk. However, few studies have examined the association between MetS and PCa progression. This retrospective study consisted of 1016 patients with PCa who received radical prostatectomy. The association between MetS and pathological features was evaluated using logistic regression analysis. Compared with patients without MetS, those with MetS indicated an increased risk of prostatectomy Gleason score (GS) ≥8 (odds ratio [OR] =1.670, 95% confidence interval (CI) 1.096-2.545, P= 0.017), and a 1.5-fold increased risk of pT3-4 disease (OR = 1.583, 95% CI 1.106-2.266, P= 0.012). The presence of MetS was an independent predictor of lymph node involvement (OR = 1.751, 95% CI 1.038-2.955, P= 0.036). Furthermore, as the number of MetS components accumulated, the risk of a GS ≥ 8 increased. The present study indicates a significant association between MetS and advanced PCa. The results need to be evaluated in large-scale prospective cohorts.